Fairness Definitions and Metrics in Deep Reinforcement Learning for Drug Discovery in Healthcare: A Rapid Evidence Review
arXiv:2606.02902v1 Announce Type: cross Abstract: Deep reinforcement learning (DRL) is increasingly applied to de novo molecular design, but choices in data, rewards, and evaluation can yield uneven performance across disease areas and chemotypes. Despite this, there is no concise synthesis of how fairness is defined, measured, and tested in DRL-based drug discovery. In this rapid evidence review, we synthesize fairness definitions and metrics for DRL-driven molecule generation in healthcare. We focus on three questions: (i) how dataset composition and split strategies, especially scaffold ver
The rapid advancement and application of DRL in drug discovery necessitates a concurrent focus on ethical implications, particularly fairness, to ensure equitable and responsible deployment.
A comprehensive understanding of fairness in DRL for drug discovery is crucial for developing robust, unbiased AI systems, preventing algorithmic harms, and ensuring trustworthy medical innovation.
The explicit focus on defining and measuring fairness in DRL for drug discovery provides a framework that can guide future research and regulatory efforts, enhancing the ethical development of AI in healthcare.
- · Ethical AI developers
- · Patients in underserved disease areas
- · Drug discovery companies prioritizing fairness
- · AI governance and regulatory bodies
- · Developers ignoring fairness considerations
- · Drug discovery models exhibiting bias
- · Patients affected by biased drug development
Increased scrutiny and demand for fairness-aware DRL models in pharmaceutical research.
Development of industry standards and benchmarks for fairness in AI-driven drug discovery, potentially leading to regulatory guidelines.
Enhanced trust in AI-generated therapeutic candidates, accelerating the adoption of DRL in real-world clinical applications and reducing health disparities.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.LG